MN/CA9 gene expression as a potential biomarker in renal cell carcinoma

@article{Murakami1999MNCA9GE,
  title={MN/CA9 gene expression as a potential biomarker in renal cell carcinoma},
  author={Murakami and Kanda and Tsuji and Kanayama and Kagawa},
  journal={BJU International},
  year={1999},
  volume={83}
}
To compare the levels of MN/CA9 expression with clinicopathological variables in renal cell carcinoma (RCC), and thus evaluate MN/CA9 expression as a possible biomarker for RCC. 
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma
To evaluate the prognostic information of carbonic anhydrase (CA) IX expression in patients with renal cell carcinoma (RCC), as increased expression of CA IX is correlated with a worse prognosis in
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma
The use of carbonic anhydrase IX as a promising molecular marker in RCC is described by authors from Los Angeles, who discuss the promise that molecular markers hold to improve diagnosis, staging,
MN/CA9 gene expression as a potential tumor marker for renal cell carcinoma.
TLDR
There is a correlation in terms of MN/CA9 expression between blood and tumor tissue samples of RCC patients as those who exhibit MN/ CA9 expression in blood were also positive at the tumor tissue levels.
CA9 Expression as a Prognostic Factor in Renal Clear Cell Carcinoma
Introduction: We investigated whether CA9 protein could be used as a prognostic tumor marker as well as a diagnostic biomarker in renal clear cell carcinoma. Materials and Methods: Nephrectomy
Basic biology and clinical behavior of renal cell carcinoma.
TLDR
Renal cell carcinoma occurs twice as often in men and most commonly occurs during the fifth through seventh decades of life, but has been reported in younger patients.
Angiogenesis in human renal cell carcinoma : hypoxia, vascularity and prognosis
TLDR
The angiogenic switch is activated by various trigger signals, such as hypoxia, low pH, and genetic mutations, which trigger tumour progression through angiogenesis.
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
  • M. Bui, D. Seligson, +12 authors A. Belldegrun
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
Lower CAIX levels are independently associated with poor survival in advanced RCC, which reflects significant changes in tumor biology, which should be used to predict clinical outcome and identify high-risk patients in need for adjuvant immunotherapy and CAIX-targeted therapies.
Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma
TLDR
Lower CAIX levels are independently associated with poor survival in advanced RCC, which reflects significant changes in tumor biology, which should be used to predict clinical outcome and identify high-risk patients in need for adjuvant immunotherapy and CAIX-targeted therapies.
Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer.
TLDR
MVD was higher in more advanced T- and N-stages and may be used as a determinant of survival in patients with rectal adenocarcinomas, and CA-9 expression was seen more often in earlier Dukes' stages, possibly representing an early tumor hypoxic response.
Original Article Expression of carbonic anhydrase-9 correlates with metastasis and prognosis of Chinese patients with invasive breast ductal carcinoma
TLDR
It is concluded that expression of CA-9 is strongly associated with neoplastic metastasis which suggests hypoxic microenvironment may play an important role in invasive breast ductal carcinoma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma
TLDR
Whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored is examined.
Serum immunosuppressive acidic protein as a tumor marker for renal cell carcinoma.
TLDR
It is suggested that serum IAP may serve as a tumor marker in patients with renal cell carcinoma and decreased within 3 months after the operation and increased with recurrence.
Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney.
TLDR
It is concluded that MN/CA9 protein expression could serve as a valuable adjunct to the cytological and histological diagnosis of benign renal cysts versus cystic R CC, adenoma versus RCC, and oncocytoma versus granular cell RCC.
Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma.
TLDR
This survey identified a unique association of MN expression with renal cell cancers, especially those of the clear cell variety, suggesting that MN is a potential marker for the diagnosis, staging, and therapeutic monitoring of renal cell carcinoma in humans.
Serum iron as a tumor marker in renal cell carcinoma.
TLDR
It was concluded that the serum iron level may be used as a useful tumor marker in staging and follow-up of renal cell carcinoma.
Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
TLDR
Ferritin may be a useful serum marker for monitoring patients with RCC, but the actual source of the ferritin remains unclear and dictates further investigation.
Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker.
TLDR
The study shows that erythropoietin is a tumor marker with a low sensitivity, however, it correlates with stage and grade and provides prognostic information.
Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma.
TLDR
Results indicate that serum gamma-enolase could be a useful tumor marker to stage disease and monitor treatment in patients with renal cell carcinoma.
Serum creatine kinase B subunit in patients with renal cell carcinoma.
TLDR
Findings indicate that serum CK-B is a useful biomarker for monitoring the clinical course for a limited number of RCC patients, but is not a marker for diagnosis and staging.
An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma.
TLDR
Findings indicate that aldolase B, the predominant isozyme in the normal case, changes into a Aldolases A and C during carcinogenesis and that serum aldOLase A could be a new useful biomarker for RCC.
...
1
2
3
...